Repligen (NASDAQ:RGEN) Trading Up 4.5% - Time to Buy?

Key Points

• Repligen's stock price rose by 4.5%, reaching last traded at $129.62, despite a significant decline in trading volume compared to its average daily volume.
• Recent analyst ratings for Repligen show a mix of outlooks, with a consensus price target of $168.75 and most analysts giving it a "Moderate Buy" rating.
• The company's quarterly earnings report revealed $182.37 million in revenue, an increase of 14.8% year-over-year, although it missed earnings per share estimates.

Repligen Corporation (NASDAQ:RGEN - Get Free Report)'s stock price was up 4.5% during mid-day trading on Tuesday . The stock traded as high as $129.12 and last traded at $129.62. Approximately 166,283 shares traded hands during trading, a decline of 79% from the average daily volume of 775,379 shares. The stock had previously closed at $124.09.

Analysts Set New Price Targets

Several research analysts have issued reports on RGEN shares. HC Wainwright restated a "buy" rating and set a $180.00 target price on shares of Repligen in a research report on Wednesday, September 3rd. Jefferies Financial Group reduced their price objective on shares of Repligen from $145.00 to $135.00 and set a "hold" rating for the company in a research note on Friday, September 12th. Stephens raised shares of Repligen to an "overweight" rating and set a $160.00 price objective for the company in a research note on Tuesday, July 22nd. Wall Street Zen downgraded shares of Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Finally, Wells Fargo & Company reduced their target price on shares of Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a report on Wednesday, July 30th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $168.75.

Repligen Stock Up 6.4%

The business's 50 day moving average is $120.41 and its 200 day moving average is $125.34. The company has a market capitalization of $7.43 billion, a price-to-earnings ratio of -530.86, a PEG ratio of 2.32 and a beta of 1.07. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The business had revenue of $182.37 million during the quarter, compared to analyst estimates of $174.62 million. During the same quarter in the previous year, the company earned $0.40 EPS. The firm's revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Sell-side analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Martin D. Madaus purchased 1,800 shares of Repligen stock in a transaction that occurred on Friday, August 8th. The stock was bought at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the transaction, the director owned 1,800 shares in the company, valued at $201,834. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 1.20% of the company's stock.

Institutional Trading of Repligen

Several institutional investors have recently bought and sold shares of the business. Texas Permanent School Fund Corp boosted its stake in shares of Repligen by 36.2% in the second quarter. Texas Permanent School Fund Corp now owns 25,141 shares of the biotechnology company's stock worth $3,127,000 after acquiring an additional 6,688 shares during the last quarter. Squarepoint Ops LLC increased its holdings in shares of Repligen by 49.7% during the 2nd quarter. Squarepoint Ops LLC now owns 73,792 shares of the biotechnology company's stock worth $9,178,000 after buying an additional 24,510 shares during the last quarter. Headlands Technologies LLC purchased a new stake in Repligen in the second quarter valued at $353,000. Tower Research Capital LLC TRC raised its holdings in Repligen by 14.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,448 shares of the biotechnology company's stock valued at $180,000 after buying an additional 179 shares during the period. Finally, Captrust Financial Advisors boosted its position in shares of Repligen by 16.8% during the second quarter. Captrust Financial Advisors now owns 6,566 shares of the biotechnology company's stock worth $817,000 after buying an additional 946 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.